NCT02242318已完成4 期
A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of Micardis® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 440
- 主要终点
- Change in 24 hour mean Diastolic blood pressure (DBP) after a missed dose
研究概览
简要总结
The primary aim of the trial is to compare telmisartan 80 mg to valsartan 160 mg in lowering diastolic blood pressure in patients who missed a dose of their medication, as measured by ABPM (change from baseline in mean DBP over 24 hours), and to compare telmisartan 80 mg to valsartan 160 mg in lowering DBP during the last six hours of the dosing interval at the end of a 6 to 8-week treatment period, as measured by ABPM (change from baseline)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, at Visit 2
- •24-hour mean DBP of ≥ 85 mmHg at Visit 3 as measured by ABPM
- •Age 18 years or older
- •Ability to stop any current antihypertensive therapy without risk to the patient (investigator's discretion)
- •Patient's written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
排除标准
- •Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who
- •are not surgically sterile,
- •are nursing,
- •are of child-bearing potential and are NOT practising acceptable methods of birth control, or do NOT plan to continue practising an acceptable method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives and Intra Uterine Devices (IUD)
- •Known or suspected secondary hypertension
- •Mean sitting SBP ≥180 mmHg or mean sitting DBP ≥110 mmHg during any visit of the placebo run-in period
- •Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- •Serum Glutamate-Pyruvate-Transaminase (Alanine Aminotransferase) (SGPT (ALT)) or Serum Glutamate-Oxaloacetate-Transaminase (Aspartate Aminotransferase) (SGOT (AST)) > than 2 times the upper limit of normal range,
- •Serum creatinine > 2.3 mg/dL (or > 203 μmol/l)
- •Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients postrenal transplant or with only one kidney
- •Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia
- •Uncorrected volume depletion
- •Primary aldosteronism
- •Hereditary fructose intolerance
- •Biliary obstructive disorders
- •Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
- •History of drug or alcohol dependency within six months prior to start of run-in period
- •Concomitant administration of any medications known to affect blood pressure, except medication allowed by the protocol
- •Any investigational therapy within one month of signing the informed consent form
- •Congestive heart failure (New York Heart Association (NYHA) functional class Congestive Heart Failure (CHF III-IV))
- •Unstable angina within the past three months prior to start of run-in period
- •Stroke within the past six months prior to start of run-in period
- •Myocardial infarction or cardiac surgery within the past three months prior to start of run-in period
- •Percutaneous Transluminal Coronary Angioplasty (PTCA) within the past three months prior to start of run-in period
- •Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
- •Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
- •Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
- •Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 Ante Meridiem (AM)
- •Known hypersensitivity to any component of the formulations
- •Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication
- •Inability to comply with the protocol
研究组 & 干预措施
Telmisartan
Experimental
low dose for two weeks, then up titration to high dose, once daily
干预措施: Placebo (Drug)
Telmisartan
Experimental
low dose for two weeks, then up titration to high dose, once daily
干预措施: Telmisartan (Drug)
Valsartan
Active Comparator
low dose for two weeks, then up titration to high dose, once daily
干预措施: Valsartan (Drug)
Valsartan
Active Comparator
low dose for two weeks, then up titration to high dose, once daily
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in 24 hour mean Diastolic blood pressure (DBP) after a missed dose
时间窗: Baseline, Day 41, Day 55
measured by ambulatory blood pressure monitoring (ABPM)
Change in mean DBP during the last 6 hours of the 24 hour dosing interval
时间窗: up to 8 weeks
次要结局
- Change in 24-hour mean systolic blood pressure (SBP) after a missed dose(Baseline, Day 41, Day 55)
- Change in mean SBP during the last 6 hours of the 24-hour dosing interval(up to 8 weeks)
- Change in pulse pressure (PP)(up to 8 weeks)
- Change in 24-hour mean DBP after an active dose of study medication(up to 8 weeks)
- Change in 24-hour mean SBP after an active dose of study medication(up to 8 weeks)
- Change in mean seated trough SBP/DBP/PP in- clinic manual cuff sphygmomanometer after a missed dose(up to 8 weeks)
- Change in the mean seated trough SBP/DBP/PP in- clinic manual cuff sphygmomanometer after an active dose of study medication(up to 8 weeks)
- Responder rate measured by ABPM after a missed dose of study medication(Baseline, Day 41, Day 55)
- Responder rate measured by ABPM after an active dose of study medication(up to 8 weeks)
- Responder rate in- clinic manual trough cuff measurements after a missed dose of study medication(Baseline, Day 41, Day 55)
- Responder rate in- clinic manual trough cuff measurements after an active dose of study medication(up to 8 weeks)
- Number of patients with adverse events(up to 8 weeks)
- Change in 24-hour Pulse Pressure (PP) after a missed dose(Baseline, Day 41, Day 55)
研究者
相似试验
已完成
4 期
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 HypertensionHypertensionNCT00168779Boehringer Ingelheim1,185
已完成
4 期
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt NephropathyDiabetic NephropathiesHypertensionNCT00153023Boehringer Ingelheim885
已完成
4 期
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II PatientsHypertensionNCT00240448Boehringer Ingelheim1,109
终止
4 期
SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk PatientsCoronary ArteriosclerosisHypertensionNCT00274105Boehringer Ingelheim22
已完成
3 期
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan MonotherapyHypertensionNCT00144222Boehringer Ingelheim218